News

Tazio Storni, Senior Investment Manager, Lydia Haueter, Senior Investment Manager & Marco Minonne Senior Investment Manager Pictet Asset Management. In a universe where innovation has the power to transform patients’ lives, but one also dominated by mergers, takeovers and bankruptcies, our Biotech strategy has stood…

Collective madness, bubble, cul-de-sac, the terms have flourished to describe the rise in AI values. The market eventually entered a rapid consolidation phase, but one sector exploded. A healthy correction, some would say, but the beginning of a crash, others insist. Some explain. Even the…

Valued at $17.3 billion and generating over $1 billion in annual recurring revenue, Deel will use the investment to advance its mission to simplify global work. Deel, the leading global HR and payroll platform, today announced a $300 million strategic investment from new investor Ribbit…

The Ghent biotech company MRM Health has suddenly moved into the spotlight after raising a record €55 million in a financing round. Under the leadership of co-founder and CEO Sam Possemiers, the company is working on a revolutionary approach: medicines made up of carefully selected…

After soaring sharply, the markets have gone into pause mode in recent weeks. In the meantime, OpenAI's CEO has spoken openly about the risk of a bubble, as the tech giants race to invest in generative AI reaches staggering sums. Meta, Alphabet, Microsoft and Amazon…

By Jan Viebig, Chief Investment Officer, ODDO BHF SE. American stock markets seem to be in a good mood again. But things are not as good as they appear. The US has many highly dynamic sectors and regions, alongside some that are far weaker. Commentators…

European mid-sized companies are showing resilience and continue to look ahead, despite a complex mix of economic and geopolitical challenges. This is the conclusion of the latest edition of the International Business Report (IBR) by Grant Thornton, a large-scale survey conducted among more than 4,000…

Innovating macrophage-targeted therapeutics across multiple therapeutic areas Proprietary functional macrophage fingerprinting technology identifies disease-relevant macrophage subsets Strengthened by the appointments of James Rush as CEO and Jim Van heusden as Chairman Powered by Bioqube Ventures’ venture creation model Spica was founded on groundbreaking research into…

An increasing number of companies are calling on the services of these people, who see themselves as the Swiss army knife of managers. Their title is in English: Chief of Staff. In French, this job title could be translated as the equally obscure "bras droit…